ASAnna-Karin Sjögren

Anna-Karin Sjögren

*This is an algorithmically generated author record based on publicly available information.

Anna-Karin Sjögren has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Mikael Persson

    Clinical Pharmacology and Safety Sciences, AstraZeneca R&D, Sweden

    3 shared publications
  • Jorrit J. Hornberg

    RIA Safety, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden

    2 shared publications
  • Katarina Breitholtz

    Mechanistic Safety and ADME Sciences, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden

    2 shared publications
  • Lucas Milton

    DMD, CVRM, IMED Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden

    2 shared publications
  • Malin Forsgard

    CVRM Safety, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden

    2 shared publications
  • Tom T.G. Nieskens

    Clinical Pharmacology and Safety Sciences, AstraZeneca R&D, Sweden

    2 shared publications

Latest Publications

  • Open Access

    Rat and human primary proximal tubule epithelial cells allow for cross-species comparisons of drug-induced nephrotoxicity in vitro

    by Stan A. Zuidervaart, Bobin G. Abraham, Paul A. Fitzpatrick, Anna-Karin Sjögren, Catherine C. Bell

    Translating nephrotoxicity risks from rat to human is hampered by species differences in kidney physiology. An in vitro rat kidney platform focused on proximal tubules, the primary site of drug-induced injury, could enable mechanistic, cross-species assessments. Here, we characterized rat primary proximal tubule epithelial cells (rPPTEC) and evaluated their use for nephrotoxicity studies in vitro. rPPTEC were characterized by gene and protein expression, and drug transporter functionality. Next, rPPTEC were exposed to 7 validation compounds (4 nephrotoxicants, 3 non-nephrotoxicants), after which cell viability was assessed with ATP and LDH assays, and high-content imaging. Finally, the toxicity response to compounds known to be more toxic in rat than in human (rat-enhanced nephrotoxicants) was compared in rPPTEC and human renal proximal tubule epithelial cells (HRPTEC). rPPTEC expressed proximal tubule markers (Aqp1, Ggt1), and functionally active drug transporters (P-gp, Oct2, Lrp2/Cubn), but lacked Oat1. The nephrotoxicants cisplatin, puromycin and cyclosporin A, but not tenofovir, induced dose-dependent decreases in ATP, increases in LDH, and alterations in imaging-based parameters. None of the non-nephrotoxicants were associated with major alterations in cell viability nor high-content imaging parameters. rPPTEC were more sensitive to the rat-enhanced nephrotoxicants zoledronate and ibandronic acid, but also to cisplatin and cyclosporin A. Notably, 45% of rPPTEC stained positive for Ki-67, compared to 0.7% of HRPTEC. rPPTEC exhibited a proximal tubular phenotype and correctly identified 6 out of 7 validation compounds. Parallel exposures in rPPTEC and HRPTEC revealed greater sensitivity of rPPTEC towards nephrotoxicants, potentially explained by the greater proliferative capacity of rPPTEC.


  • Nephrotoxic antisense oligonucleotide SPC5001 induces kidney injury biomarkers in a proximal tubule-on-a-chip

    by Tom T. G. Nieskens, Otto Magnusson, Patrik Andersson, Magnus Söderberg, Mikael Persson, Anna-Karin Sjögren

    Antisense oligonucleotides (ASOs) are a promising therapeutic modality. However, failure to predict acute kidney injury induced by SPC5001 ASO observed in a clinical trial suggests the need for additional preclinical models to complement the preceding animal toxicity studies. To explore the utility of in vitro systems in this space, we evaluated the induction of nephrotoxicity and kidney injury biomarkers by SPC5001 in human renal proximal tubule epithelial cells (HRPTEC), cultured in 2D, and in a recently developed kidney proximal tubule-on-a-chip. 2D HRPTEC cultures were exposed to the nephrotoxic ASO SPC5001 or the safe control ASO 556089 (0.16–40 µM) for up to 72 h, targeting PCSK9 and MALAT1, respectively. Both ASOs induced a concentration-dependent downregulation of their respective mRNA targets but cytotoxicity (determined by LDH activity) was not observed at any concentration. Next, chip-cultured HRPTEC were exposed to SPC5001 (0.5 and 5 µM) and 556089 (1 and 10 µM) for 48 h to confirm downregulation of their respective target transcripts, with 74.1 ± 5.2% for SPC5001 (5 µM) and 79.4 ± 0.8% for 556089 (10 µM). During extended exposure for up to 20 consecutive days, only SPC5001 induced cytotoxicity (at the higher concentration; 5 µM), as evaluated by LDH in the perfusate medium. Moreover, perfusate levels of biomarkers KIM-1, NGAL, clusterin, osteopontin and VEGF increased 2.5 ± 0.2-fold, 3.9 ± 0.9-fold, 2.3 ± 0.6-fold, 3.9 ± 1.7-fold and 1.9 ± 0.4-fold respectively, in response to SPC5001, generating distinct time-dependent profiles. In conclusion, target downregulation, cytotoxicity and kidney injury biomarkers were induced by the clinically nephrotoxic ASO SPC5001, demonstrating the translational potential of this kidney on-a-chip.


  • Open Access

    A Multicompartment Human Kidney Proximal Tubule-on-a-Chip Replicates Cell Polarization–Dependent Cisplatin Toxicity

    by Tom T.G. Nieskens, Mikael Persson, Edward J. Kelly, Anna-Karin Sjögren

    Drug-induced kidney injury (DIKI) is a major clinical problem and causes drug attrition in the pharmaceutical industry. To better predict DIKI, kidney in vitro cultures with enhanced physiological relevance are developed. To mimic the proximal tubule, the main site of adverse drug reactions in the kidney, human-derived renal proximal tubule epithelial cells (HRPTEC) were injected in one of the channels of dual channel Nortis® chips and perfused for 7 days. Tubes of HRPTEC demonstrated expression of tight junction protein 1 (ZO-1), lotus lectin and primary cilia, with localization at the apical membrane, indicating an intact proximal tubule brush border. Gene expression of cisplatin efflux transporters MATE1 (SLC47A1) and MATE2-k (SLC47A2), and Megalin endocytosis receptor (LRP2) increased 19.9{plus minus}5.0, 23.2{plus minus}8.4 and 106{plus minus}33-fold, respectively, in chip cultures compared to 2D cultures. Moreover, organic cation transporter 2 (OCT2, SLC22A2) was localized exclusively on the basolateral membrane. When infused from the basolateral compartment, cisplatin (25 µM, 72 h) induced toxicity, evident as reduced cell number and reduced barrier integrity compared to vehicle-treated chip cultures. Co-exposure with the OCT2 inhibitor cimetidine (1 mM) abolished cisplatin toxicity. In contrast, infusion of cisplatin from the apical compartment did not induce toxicity, in line with polarized localization of cisplatin uptake transport proteins, including OCT2. In conclusion, we developed a dual channel human kidney proximal tubule-on-a-chip with a polarized epithelium, restricting cisplatin sensitivity to the basolateral membrane, suggesting improved physiological relevance over single compartment models. Its implementation in drug discovery holds promise to improve future in vitro DIKI studies. Significance Statement Human-derived kidney proximal tubule cells retained characteristics of epithelial polarization in vitro when cultured in the kidney-on-a-chip, and the dual channel construction allowed for drug exposure using the physiologically-relevant compartment. Therefore, cell polarization-dependent cisplatin toxicity could be replicated for the first time in a kidney proximal tubule-on-a-chip. The use of this physiological relevant model in drug discovery has potential to aid identification of safe novel drugs and contribute to reducing attrition rates due to drug-induced kidney injury.


  • A novel multi-parametric high content screening assay in ciPTEC-OAT1 to predict drug-induced nephrotoxicity during drug discovery

    by Anna-Karin Sjögren, Katarina Breitholtz, Ernst Ahlberg, Lucas Milton, Malin Forsgard, Mikael Persson, Simone H. Stahl, Martijn J. Wilmer, Jorrit J. Hornberg

    Drug-induced nephrotoxicity is a major concern in the clinic and hampers the use of available treatments as well as the development of innovative medicines. It is typically discovered late during drug development, which reflects a lack of in vitro nephrotoxicity assays available that can be employed readily in early drug discovery, to identify and hence steer away from the risk. Here, we report the development of a high content screening assay in ciPTEC-OAT1, a proximal tubular cell line that expresses several relevant renal transporters, using five fluorescent dyes to quantify cell health parameters. We used a validation set of 62 drugs, tested across a relevant concentration range compared to their exposure in humans, to develop a model that integrates multi-parametric data and drug exposure information, which identified most proximal tubular toxic drugs tested (sensitivity 75%) without any false positives (specificity 100%). Due to the relatively high throughput (straight-forward assay protocol, 96-well format, cost-effective) the assay is compatible with the needs in the early drug discovery setting to enable identification, quantification and subsequent mitigation of the risk for nephrotoxicity.


  • Development of a high content assay in ciPTEC-OAT1 as an in vitro model to predict drug-induced nephrotoxicity

    by Anna-Karin Sjogren, Katarina Breitholtz, Malin Forsgard, Lucas Milton, Simone Stahl, Katherine Fenner, Martijn Wilmer, Mikael Persson, Jorrit Hornberg

  • Critical differences in toxicity mechanisms in induced pluripotent stem cell-derived hepatocytes, hepatic cell lines and primary hepatocytes

    by Anna-Karin M. Sjogren, Maria Liljevald, Björn Glinghammar, Johanna Sagemark, Xue-Qing Li, Anna Jonebring, Ian Cotgreave, Gabriella Brolén, Tommy B. Andersson

    Human-induced pluripotent stem cell-derived hepatocytes (hiPSC-Hep) hold great potential as an unlimited cell source for toxicity testing in drug discovery research. However, little is known about mechanisms of compound toxicity in hiPSC-Hep. In this study, modified mRNA was used to reprogram foreskin fibroblasts into hiPSC that were differentiated into hiPSC-Hep. The hiPSC-Hep expressed characteristic hepatic proteins and exhibited cytochrome P450 (CYP) enzyme activities. Next, the hiPSC-Hep, primary cryopreserved human hepatocytes (cryo-hHep) and the hepatic cell lines HepaRG and Huh7 were treated with staurosporine and acetaminophen, and the toxic responses were compared. In addition, the expression of genes regulating and executing apoptosis was analyzed in the different cell types. Staurosporine, an inducer of apoptosis, decreased ATP levels and activated caspases 3 and 7 in all cell types, but to less extent in Huh7. Furthermore, a hierarchical clustering and a principal component analysis (PCA) of the expression of apoptosis-associated genes separated cryo-hHep from the other cell types, while an enrichment analysis of apoptotic pathways identified hiPSC-Hep as more similar to cryo-hHep than the hepatic cell lines. Finally, acetaminophen induced apoptosis in hiPSC-Hep, HepaRG and Huh7, while the compound initiated a direct necrotic response in cryo-hHep. Our results indicate that for studying compounds initiating apoptosis directly hiPSC-Hep may be a good alternative to cryo-hHep. Furthermore, for compounds with more complex mechanisms of toxicity involving metabolic activation, such as acetaminophen, our data suggest that the cause of cell death depends on a balance between factors controlling death signals and the drug-metabolizing capacity.


  • Monozygotic twins discordant for intermittent allergic rhinitis differ in mRNA and protein levels

    by A.‐K. M. Sjogren, F. Barrenas, A. Muraro, M. Gustafsson, P. Sætrom, H. Wang, M. Benson

    Monozygotic (MZ) twins discordant for complex diseases may help to find disease mechanisms that are not due to genetic variants. Intermittent allergic rhinitis (IAR) is an optimal disease model because it occurs at defined time points each year, owing to known external antigens. We hypothesized that MZ twins discordant for IAR could help to find gene expression differences that are not dependent on genetic variants. We collected blood outside of the season from MZ twins discordant for IAR, challenged their peripheral blood mononuclear cells (PBMC) with pollen allergen in vitro, collected supernatants and isolated CD4+ T cells. We identified disease‐relevant mRNAs and proteins that differed between the discordant MZ twins. By contrast, no differences in microRNA expression were found. Our results indicate that MZ twins discordant for IAR is an optimal model to identify disease mechanisms that are not due to genetic variants.


  • Open Access

    GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS–induced lung cancer

    by Anna-Karin M. Sjogren, Karin M.E. Andersson, Meng Liu, Briony A. Cutts, Christin Karlsson, Annika M. Wahlstrom, Martin Dalin, Carolyn Weinbaum, Patrick J. Casey, Andrej Tarkowski, et al.

    Protein geranylgeranyltransferase type I (GGTase-I) is responsible for the posttranslational lipidation of CAAX proteins such as RHOA, RAC1, and cell division cycle 42 (CDC42). Inhibition of GGTase-I has been suggested as a strategy to treat cancer and a host of other diseases. Although several GGTase-I inhibitors (GGTIs) have been synthesized, they have very different properties, and the effects of GGTIs and GGTase-I deficiency are unclear. One concern is that inhibiting GGTase-I might lead to severe toxicity. In this study, we determined the effects of GGTase-I deficiency on cell viability and K-RAS–induced cancer development in mice. Inactivating the gene for the critical β subunit of GGTase-I eliminated GGTase-I activity, disrupted the actin cytoskeleton, reduced cell migration, and blocked the proliferation of fibroblasts expressing oncogenic K-RAS. Moreover, the absence of GGTase-I activity reduced lung tumor formation, eliminated myeloproliferative phenotypes, and increased survival of mice in which expression of oncogenic K-RAS was switched on in lung cells and myeloid cells. Interestingly, several cell types remained viable in the absence of GGTase-I, and myelopoiesis appeared to function normally. These findings suggest that inhibiting GGTase-I may be a useful strategy to treat K-RAS–induced malignancies.